In today’s era of precision medicine, the management of most solid tumors is increasingly driven by biomarker testing, the results of which often drive treatment decisions. Perhaps the first real-world example of this is breast cancer, where biomarker testing has been well established for several decades. For most other solid tumors, biomarker testing has been adopted relatively recently.